Skip to main content
. 2021 Sep 15;15:3915–3925. doi: 10.2147/DDDT.S321330

Figure 2.

Figure 2

MRM mass spectra of rociletinib (RLC) (A) and bosutinib (internal standard; IS) (B) presenting the proposed fragmentation pattern.